LYONS GARY A 4

What Happened Gary A. Lyons, a director of Neurocrine Biosciences (NBIX), reported the conversion/exercise of 1,659 derivative units into 1,659 shares on May 21, 2026. The filing shows an acquisition of 1,659 shares at $0.00 and a corresponding disposition of 1,659 shares (derivative) at $0.00. The reported per‑share price and total value for these entries are $0.00.

Key Details

• Transaction date: 2026-05-21; transaction code M (exercise or conversion of a derivative security).
• Amounts: 1,659 shares acquired @ $0.00 and 1,659 shares disposed @ $0.00 (derivative).
• Footnote: 116,158 of the reporting person’s shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12; he has voting and investment power over that trust (F1).
• RSU context: Each RSU converts to one share on vesting (F2). The RSU award was granted 2025-05-21 and is fully vested (F3).
• Filing timeliness: Reported on 2026-05-21 for a 2026-05-21 transaction — no late filing flag indicated.

Context This filing documents a derivative conversion tied to vested Restricted Stock Units (RSUs). It is common for RSU vesting to be reported as both an acquisition (conversion into shares) and a simultaneous disposition/settlement in Form 4 reporting; the $0.00 exercise price reflects that these were vested RSUs rather than a cash option purchase. The filing is informational and does not, by itself, indicate directional trading intent.